One of us (M.A.H.) has known Dr. Eric Rose since he was a resident at Columbia University, then when he became a fellow in cardiothoracic surgery, and later, when he became a director, first of the heart transplantation program, then of the Cardiothoracic Division, and finally as Valentine Mott/Johnson & Johnson Professor and Chairman of the Department of Surgery, a position he has held for the last 14 years. Having this long relationship with Dr. Rose, I was not sure where or how to begin this tribute to my former resident, long-time colleague and collaborator, and eventually director. It was as an innovative and courageous Chairman that Dr. Rose had a major impact on me when he appointed me as a Residency Program Director. Through his remarkable interest and support of educational changes, the surgical residency at Columbia-NY Presbyterian Hospital has become one of the leading programs in the country. But the greatest inspiration that Dr. Rose brought to the Department of Surgery was his fearless and relentless support of ventures into the unknown. When faced with formalizing heart transplantation as a junior faculty member, he went on to lay the foundation for the largest heart transplant program in the world; when challenged by development and lack of acceptance of left ventricular assist devices, he guided their approval after appropriate multi-institutional studies had led to their adoption as standard of care. His influence extended to the support of a Pancreatic Islet Transplantation Program inspired by his predecessor and mentor, Dr. Keith Reemtsma. Doctor Rose invested in and encouraged both the clinical and experimental development of this program under my guidance as part of his dedication to innovation.
Following the remarkable early success of the Edmonton group with its steroid-free protocol for clinical pancreatic islet transplantation introduced in 2001, 10 other units, including the one at Columbia, have attempted to duplicate this effort with the support of the National Institutes of Health (NIH). With Dr. Rose's support, and that of colleagues in other departments, The Regional Columbia Pancreatic Islet Center joined the NIH Consortium [1] . The initial success at Columbia was limited to only two successful clinical transplants, and the efficacy of this treatment lasted only 6 months. As we learned that other researchers who had transplanted more patients had limited success in having their recipients stay off insulin for more than 4 or 5 years [2] , we returned to experimental work. The focus of that work was on development of a site for islet implantation, other than intrahepatic, to avoid early islet destruction by an inflammatory storm, poor engraftment, and possible intense exposure to higher toxic levels of immunosuppressive drugs in the liver. Our experiments focused again [3] on the intramuscular route of islet implantation, this time using preconditioning of the recipients with three-dimensional alginate scaffolds modified with vascular endothelial-derived growth factor (VEGF) and platelet-derived growth factor (PDGF) in combination to promote ingrowth of functionally sound vessels [4] . In addition to these growth factors, we modified alginate with the cyclic extracellular matrix signaling molecule arginineglycine-aspartic acid peptide motif (RGD), which has been shown to enhance cellular adhesion and prevent transmembrane apoptotic signaling via integrins [5] [6] [7] . The intent in adding these factors was to improve islet engraftment by avoiding low levels of neovascularization. The choice of intramuscular site mimicked that of parathyroid autotransplantation, and we felt the experiment was safer and more easily monitored without biopsies. It also offered the possibility of eventual local immunosuppression, either with co-stimulatory blockade with monoclonal antibodies attached to the scaffold or with the use of immature dendritic cells co-transplanated with the islets [8] [9] [10] .
The aims of the initial experiments were to study both the efficacy of islet isografts with the use of scaffolds and the development of new methods of monitoring pancreatic islet survival using positron emission spectrometry (PET) scanning techniques with available ligands. We then combined the experiments because such monitoring is best done intramuscularly and is not practical when the islets are in the liver because of the overwhelming background noise from the ligand.
The preliminary transplantation experiments using pancreatic islet isografts (2,400 islets/recipient) into streptozotocin-induced diabetic Lewis rats primarily addressed the issues of neovascularization and engraftment at an intramuscular site. The islets were [90% pure. The relatively newer methods, published elsewhere [11] [12] [13] and since modified by us and submitted elsewhere for publication [14] , included priming of the alginate scaffolds with VGEF, PDGF, and then with RGD prior to intramuscular implantation in the abdominal wall of each diabetic recipient of the scaffold, either modified or unmodified (controls) 14 days before islet transplantation. This delay was to permit the area to be neovascularized before islet transplantation on day 0 (Figs. 1, 2 ).
Detailed analysis of neovascularization at the transplant site just before islet implantation and at 2 weeks after implantation with immunostaining revealed fibrovascular tissue-penetrating scaffolds. In addition, there were significantly higher numbers of capillaries stained with factor VIII-related antigen per high power field in the scaffold group containing VEGF/PDGF than in the other groups, by a factor of 2-5; P \ 0.05. Islet isograft survival for more than 2 months, as measured by normalized fasting blood sugar (FBS) and weekly glucose tolerance test (GTT), was striking (100%) in the neovascularized groups preconditioned with modified scaffolds as compared to controls, some of which (20-40%) maintained improved but not normalized blood glucose, as the islets were isografts and therefore were not rejected. When scaffolds were removed at 2 months, the animals reverted to being fully diabetic again. The details of these experiments, including the methodology, immunopathology, and results have been submitted for publication elsewhere [14] .
As a result of our expanding activities in clinical islet transplantation we, under the leadership of one of the coauthors (P.H.), also turned our attention to the issue of noninvasive monitoring of islet function after transplantation or after the onset of diabetes. At present, islet allografts are monitored by metabolic measures that only detect graft dysfunction after substantial islet mass has already been lost [15] . The noninvasive beta cell imaging technique that we recently developed relies on the use of PET with [
11 C] dihydrotetrabenazine (DTBZ) as a means of quantitating vesicular monoamine transporter type 2 (VMAT2), which is highly expressed (relative to other cells) in the beta cells of pancreas as they are located close to insulin vesicles. This method cannot be applied to islets infused into the liver because liver and bile are routes of DTBZ excretion and have a high background signal, which affects monitoring. The approach originated by the use of gene profiling of purified human islets resulted from our islet transplantation program [16] .
After islet transplantation to the intramuscular space, the PET scans with [ 11 C] DTBZ demonstrated that the transplanted and viable beta cell mass can be visualized and quantified. The transplanted islets were visualized in animals that had gel ? VEGF/PDGF/RGD modified scaffolds and that were normoglycemic, whereas those in the shamoperated controls were not visible. It was also interesting to note that the native pancreas in streptozotocin-treated animals had lower tracer binding, which confirms that reversal of hyperglycemia was not due to a residual beta cell mass in the native pancreas. This approach has now been used in humans and is detailed in previous publications [17, 18] .
We have briefly described the most recent experimental studies on islet transplantation performed in our laboratory, based on earlier unsuccessful attempts at long-term or permanent reversal of diabetes mellitus in patients. Dr. Rose has played an important catalytic role in this work. In line with his major interest in translational research, the studies described here have a great translational potential, both for cellular transplantation and for development of a tool for diagnosis of disease progression or prevention in diabetes mellitus and of pancreatic islet allograft survival following transplantation.
